BioSpace News Archive

Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly

The actions - which include a $60 million joint investment with LISC and $40M in grant funding - will support more than 2,000 Black-owned businesses and businesses owned by other underrepresented individuals, and address deeply entrenched structural racism and the trauma and economic inequity it creates [26-June-2020] OAKLAND, Calif. , June 26, 2020 /PRNewswire/ -- Ka

Medcolcanna Organics Inc. (“ Medcolcanna ”, “ MCCN ” or “the “ Company ”) (TSXV: MCCN), a leading Colombian and global integrated Cannabis Company, is pleased to provide an operational update and announce that it intends to proceed with a bridge debenture financing with the principal amount of $1,000,000 (the “ Offering ”). The Company intends to use the net proceeds from the financing for inventory production, inventory purchase, product ro

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance treatment in acrome

Radiant Ventures, Inc., a cannabis supply chain management company with manufacturing and distribution operations in California, today announced the hiring of Virender Ahluwalia as Chief Financial Officer

Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 34,848,484 shares of its common stock, including 4,545,454 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a public offering pric

ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2019; - Allocation of the financial year’s r

DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between Gilead

Joann Sweasy, PhD, interim director for the past nine months, has been named director of the University of Arizona Cancer Center, and the inaugural holder of the Nancy C. and Craig M. Berge Endowed Chair for the director of the Cancer Center.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement (“Agreement”) with a leading global pharmaceutical company (“GlobalCo”) engaged in the research, development, manufacture and marketing of pharmaceutical products.